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The efficient delivery of therapeutic drugs into interested cells is a critical challenge to broad application of nonviral vector
systems. In this research, emtansine (DM1)-loaded star-shaped folate-core polylactide-D-α-tocopheryl polyethylene glycol
1000 succinate (FA-PLA-TPGS-DM1) copolymer which demonstrated superior anticancer activity in vitro/vivo in comparison
with linear FA-PLA-TPGS nanoparticles was applied to be a vector of DM1 for FR+ breast cancer therapy. The DM1- or
coumarin 6-loaded nanoparticles were fabricated, and then characterized in terms of size, morphology, drug encapsulation
efficiency, and in vitro drug release. And the viability of MCF-7/HER2 cells treated with FA-DM1-nanoparticles (NPs) was
assessed. Severe combined immunodeficient mice carrying MCF-7/HER2 tumor xenografts were treated in several groups
including phosphate-buffered saline control, DM1, DM1-NPs, and FA-DM1-NPs. The antitumor activity was then assessed
by survival time and solid tumor volume. All the specimens were prepared for formalin-fixed and paraffin-embedded
tissue sections for hematoxylin-eosin staining. The data showed that the FA-DM1-NPs could efficiently deliver DM1 into
MCF-7/HER2 cells. The cytotoxicity of DM1 to MCF-7/HER2 cells was significantly increased by FA-DM1-NPs when
compared with the control groups. In conclusion, the FA-DM1-NPs offered a considerable potential formulation for FR+
tumor-targeting biotherapy.
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Biodegradable nanoparticles served as drug carriers that
could provide an ideal solution to most of the problems
presented by anticancer drugs [1,2]. When compared with
standard administration, drug incorporation into nanoparti-
cles shows a variety of advantages such as high stability,
protection of incorporated labile drugs from degradation,
controlled and sustained drug release, increased drug the-
rapeutic efficacy, and reduced side effects [3,4]. Polymers,
including star-shaped cholic acid-core polylactide-D-α-
tocopheryl polyethylene glycol 1000 succinate (PLA-TPGS)
copolymer, PLA-TPGS-b-poly(ε-caprolactone-ran-lactide)
(TPGS-b-(PCL-ran-PLA)) copolymer, and other structure
copolymers, have been used to develop drug-loaded nano-
particles [5,6].
Similar to vinca alkaloids, maytansine and its analogs
emtansine (DM1) which are microtubule-targeted drugs
binding to tubulin at the vinca binding site can depolymerize* Correspondence: txljd2006@126.com
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in any medium, provided the original work is pmicrotubules and arrest cells in mitosis, resulting in a
powerful anti-mitotic activity [7-10]. Maytansine displays
almost 100 times higher cytotoxicity in cells than the vinca
alkaloids [11,12]. Maytansine is effective against breast can-
cer, lung carcinoma, and murine melanocarcinoma solid tu-
mors and has an antileukemic activity against lymphocytic
leukemia in vivo [13]. The microtubule-targeted antipro-
liferative activity of maytansine/maytansinoids was substan-
tiated in a screening of 60 human cancer cell types by the
U.S. National Cancer Institute [13]. Although maytansine
and DM1 efficiently inhibits microtubule assembly and
then kills cancer cells, they demonstrated a small thera-
peutic window in human clinical trials [13,14]. The limita-
tion of maytansine and DM1 is their systemic toxicity such
as neurotoxicity and gastrointestinal tract adverse reaction
[14,15]. Nevertheless, the powerful cytotoxicity of maytansi-
noids would make them valuable for anticancer therapies if
tissue-specific drug delivery approaches are employed.
To achieve more active targeting, maytansinoids-loaded
nanoparticle surface could be immobilized by functional
molecules which can recognize and adhere to biomarkers
on the surface of target cancer cells. Among targetingOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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associated receptors, folate (FA) has been widely utilized
for targeted delivery of drug-loaded nanoparticles into FR+
tumor cells as a ligand for a folate receptor (FR) overex-
pressed in a wide range of tumors including those of the
ovary, brain, kidney, breast, and myeloid [16-18]. Recently,
it has been reported that FA-mediated delivery of drug-
loaded nanoparticles can enable binding, promote up-
take, and increase cytotoxicity to cancer cells in vitro/
vivo [19-22].
In the present study, DM1-loaded-core PLA-TPGS
copolymer nanoparticles (DM1-NPs) immobilized with
FA which can enhance tumor cell-targeting ability were
constructed. Characterization of the FA-modified DM1-
loaded-core PLA-TPGS copolymer nanoparticles (FA-
DM1-NPs), including size and zeta potential, was carried
out. And drug entrapment efficiency, drug loading effi-
ciency, and release properties in vitro were also tested.
The targeting effect of FA-DM1-NPs was investigated
in vitro through the uptake of fluorescent nanoparticles by
FR+ MCF-7/HER2 cells. The results demonstrated that
the FA-DM1-NPs and the stable DM1 methyl thioether
derivative (S-DM1) could inhibit cell proliferation, arrest
the mitotic process, and induce apoptosis in association
with suppression of microtubule dynamic stability.
Methods
Material
Human breast adenocarcinoma cell line MCF-7/HER2(ER+,
HER2-HIGH) was obtained from the American Type
Culture Collection (ATCC; Rockville, MD, USA). TPGS,
4′-6′-diamino-2-phenylindole (DAPI), and PLA (Mw ap-
proximately 25,000) were purchased from Sigma-Aldrich
(St. Louis, MO, USA). DM1 and S-DM1 was commercial-
ized by Genentech. FA-PLA-TPGS copolymers (Mw ap-
proximately 23,000) were obtained from the Graduate
School at Shenzhen, Tsinghua University. Antibodies
against caspase-3/-8/-9 were obtained from Cell Signaling
Technology (Beverly, MA, USA). Antibodies against Bcl-2
were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). All chromatographic solvents were of
high-performance liquid chromatography (HPLC)-grade
quality. And all other chemicals used were of the highest
grade commercially available.
Fabrication of DM1-loaded nanoparticles
A modified nanoprecipitation method was used to entrap
DM1 into the FA-PLA-TPGS NPs [23,24]. Briefly, a pre-
weighed amount of DM1 drug powder and 100 mg of FA-
PLA-TPGS copolymer were dissolved in 8 mL of acetone
by vortexing and sonication. The resulting nanoparticle
suspension was stirred at room temperature overnight to
remove acetone completely. The nanoparticle suspension
was centrifuged at 25,000 rpm for 15 min, and thenwashed 2 to 3 times to remove the emulsifier and
unloaded drug. This mixture was dropwise added into
100 mL 0.03% TPGS aqueous solution under stirring. In
the end, the dispersion was lyophilized 48 h for further
use. DM1-loaded PLA-TPGS NPs (DM1-PLA-TPGS-NPs)
coumarin 6-loaded star FA-PLA-TPGS-NPs (coumarin 6-
NPs), and linear FA-PLA-TPGS nanoparticles used as
control were fabricated in a similar manner.
Characterization of DM1-loaded nanoparticles
Size, surface charge, and morphology of the NPs
The nanoparticle size and zeta potential were determined by
Malvern Mastersizer 2000 (Zetasizer Nano ZS90, Malvern
Instruments Ltd., Malvern, Worcestershire, UK). All mea-
surements were measured at room temperature after
equilibration for 10 min. Average size and zeta potential
of different NPs were analyzed using a dynamic light-
scattering detector (Zetasizer Nano ZS90, Malvern In-
struments Ltd., Malvern, Worcestershire, UK). The data
were obtained with the average of three measurements.
The surface morphology of nanoparticles was examined
by a field emission scanning electron microscopy (FESEM,
JEOL JSM-6301 F, JEOL, Tokyo, Japan). To prepare sam-
ples for FESEM, the nanoparticles were fixed on the stub
by a double-sided sticky tape and then coated with a plat-
inum layer by JFC-1300 automatic fine platinum coater
(JEOL, Tokyo, Japan). Morphological examination of FA-
PLA-TPGS-NPs was performed using transmission elec-
tron microscopy (H600, Hitachi, Tokyo, Japan).
Drug content and entrapment efficiency
To determine the contents of drug loading (LC) and
entrapment efficiency (EE) of the FA-DM1-NPs, a pre-
determined amount of nanoparticles were dissolved in
1 mL methylene dichloride under vigorous vortexing.
The solution was transferred to 5 mL of mobile phase
consisting of acetonitrile and deionized water (50:50, v/v).
A nitrogen stream was introduced to evaporate the methy-
lene dichloride for approximately 20 min. And then a clear
solution was obtained for high-performance liquid chro-
matography (HPLC) analysis (LC 1200, Agilent Tech-
nologies, Santa Clara, CA, USA). A reverse-phase C18
column (250 mm× 4.6 mm, 5 μm, C18, Agilent Technolo-
gies, Santa Clara, CA, USA) was used at 25°C. The flow
rate of mobile phase was 1 mL/min. The column effluent
was detected using a UV detector at λmax of 227 nm. The
measurement was performed in triplicate. Drug loading
and encapsulation efficiency of the drug-loaded nanoparti-
cles were calculated according to the following equations,
respectively.
LC %ð Þ ¼ Weight of DM1 in the nanoparticlesð Þ=
Weight of the nanoparticlesð Þ  100%
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Briefly, 10 mg of FA-DM1-NPs were introduced into
Eppendorf tubes and dissolved in 1 mL acetonitrile and
diluted by 0.1 M citric acid. Meanwhile, the amount of
DM1 in the solution was determined by HPLC.
Drug-release assay study
The in vitro release profile of DM1 from FA-DM1-NPs
was determined by measuring the residual amount of
DM1 presented in the nanoparticles [25]. In brief, 5 mg of
accurately weighted lyophilized nanoparticles (FA-DM1-
NPs) were put into a centrifuge tube and redispersed in
8 mL phosphate buffer solution (PBS, containing 0.1%w/v
Tween 80, pH 7.4). The tube was put into an orbital
shaker water bath and vibrated at 130 rpm at 37°C. At cer-
tain time intervals, the tube was taken out and centrifuged
at 25,000 rpm for 15 min. The supernatant was then
transferred into a glass test tube for HPLC analysis. The
pellet was resuspended in 8 mL fresh PBS buffer and put
back into the shaker bath for subsequent determination.
The accumulative release of DM1 from nanoparticles was
plotted against time.
Evaluation of the biological function of FA-DM1-NPs
Cellular uptake of FA-coumarin 6-NPs
In this research, coumarin 6 served as a model control
molecule, which can be entrapped in star-shaped FA-
PLA-TPGS NPs for qualitative and quantitative studying
on cellular uptake by MCF-7/HER2 cells. Cells incu-
bated with 250 μg/mL coumarin 6-NPs at 37°C for
determined time (12, 24, and 36 h) were rinsed with cold
PBS solution three times, and then fixed by methanol
for 25 min. Cells were stained with DAPI for 30 min to
display the nuclei and rinsed twice with a PBS solution
[26,27]. Tumor cells were observed by using confocal
laser scanning microscopy (CLSM; LSM 410, Zeiss, Jena,
Germany) with an imaging software.
In vitro cytotoxicity of FA-DM1-NPs
MCF-7/HER2 cells were seeded in 96-well plates at the
density of 5 × 103 viable cells per well in 100 μL of cul-
ture medium and incubated overnight. Cells were then
treated with various suspension concentrations ranging
from 0.001 to 10.0 μg/mL of DM1 and FA-DM1-NPs for
48 and 72 h at 37°C in a CO2 incubator. At certain time
intervals, the nanoparticles were replaced with DMEM
containing MTT (5 mg/mL) and cells were then incu-
bated for an additional 4 h. MTT was aspirated off, and
DMSO was added to each well to solubilize the forma-
zan crystals formed in viable cells. The absorbance of
each well was recorded at 570 nm using a 96-well
microplate reader. Viability of untreated cells was set at100%, and absorbance of wells with medium and without
cells was set as zero. All of the results were from at least
triplicate experiments. The inhibitory concentration
IC50, the drug concentration at which cell growth was
inhibited by 50% relative to untreated control cells, was
calculated by curve fitting of the cell viability vs. drug
concentration data [28,29].
In vivo assay of drug sensitivity
The Administrative Committee on Animal Research in
the Anhui University of Science and Technology approved
all the protocols for the proposed human breast cancer
cell lines and animal experiments. Female BALB/c nude
mice of 15 to 20 g and 4 to 5 weeks old were purchased
from the Institute of Laboratory Animal Sciences, Chinese
Academy of Medical Science. MCF-7/HER2 cells in the
medium were inoculated subcutaneously to mice in the
amount of 2 × 106 cells per mouse at the right axilla, and
the subcutaneous tumor growth in each mouse was moni-
tored. The length and width of tumors were determined
by a vernier caliper, and the tumor volume (V) was calcu-
lated as V = d2 ×D/2, where d and D are the shortest and
the longest diameter of the tumor in mm, respectively
[30]. When the tumor volume reached approximately
50 mm3 (set as the 0 day), treatments were performed.
The mice were randomly divided into three groups (each
group has 10 mice, n =10). The two formulations of DM1,
i.e., the drug FA-DM1-NPs and Kadcyla®, were injected via
intra-tumoral at a single dose of 10 mg DM1/kg in PBS on
days 10, 13, and 16. PBS served as the control. Mice were
sacrificed by decapitation 30 days after treatment. The
terminal tumor weight (mg) was determined and applied
to evaluate the antitumor effects.
Immunohistochemistry
Xenograft tumor tissues were fixed in phosphate-buffered
formalin, embed in paraffin, and cut in 4 μm thickness.
Sections were deparaffinized and stained with hematoxylin-
eosin (H&E). For immunohistochemistry (IHC), tissue
sections were covered with 10 mM sodium citrate buffer,
pH 6.0, and heated in a convection steamer for 1 h. After
being blocked in 5% normal goat blocking serum for
30 min, it was incubated with primary antibody for 1 h,
and next as IHC operation.
Fluorescence in situ hybridization (FISH)
Her2 gene copy numbers were determined by using the
dual-color fluorescence in situ hybridization (FISH). After
trypsinization and washing with PBS, the cells were fixed
with methanol-acetic acid (3:1) and air-dried on slides. A
bacterial artificial chromosome (BAC) clone specific to
Her2 DNA was labeled with dUTP-FITC (Fermentas,
Burlington, Canada) and the chromosome 17 centromere
probe (p17H8) was labeled with chromatide Alexa Fluor
Table 1 Characterization of DM1-loaded nanoparticles
Polymer Particle size (nm) PDI ZP (mV) LC (%) EE (%)
PLA-TPGS-DM1 123.7 ± 3.9 0.199 −19.5 ± 2.6 8.55 76.01
FA-PLA-TPGS-DM1 126.6 ± 3.5 0.154 −12.0 ± 2.1 10.35 84.03
PDI, polydispersity index; ZP, zeta potential; LC, loading content; EE, entrapment efficiency. n =3.
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translation, and FISH was performed as described previ-
ously [31].
Western blot
The expression levels of procaspase-3/-8/-9 and Bcl-2 in
the breast cancer cells treated with S-DM1 or FA-DM1-
NPs were analyzed by Western blot. Protein was extracted
and separated by SDS-PAGE and transferred to nitrocellu-
lose membranes. After being blocked in 5% bovine serumFigure 1 The physical properties of the star-shaped FA-PLA-TPGS nan
nanoparticles detected by DLS. (B) FESEM image of the star-shaped FA-PLA
FA-PLA-TPGS NPs. (D) Typical 1H NMR spectra of FA-PLA-TPGS copolymers.albumin (w/v) at room temperature for 1 h, the membranes
were rinsed and incubated at 4°C overnight with primary
anti-total and procaspase-3/-8/-9, β-actin antibody (1:1,000).
The membranes were then washed and incubated with sec-
ondary antibody (1:2,000 ~ 3,000) at room temperature
for 1 h, developed with chemiluminescence ECL reagent
(LumiGold, SignaGen, Gaithersburg, MD, USA), and ex-
posed to Hyperfilm MP (GE Healthcare, Piscataway, NJ,
USA). Tumor samples were lysed in RIPA buffer (50 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.1% SDS,oparticles. (A) Size distribution of the star-shaped FA-PLA-TPGS
-TPGS nanoparticles. (C) Zeta potential distribution of the star-shaped
Figure 2 In vitro drug release of FA-DM1-NPs. A rapid release was
observed from 0 to 5 days, with a cumulative release percentage of
39.2% (linear FA-PLA-TPGS nanoparticles) and 53.4% (star FA-PLA-TPGS
nanoparticles) in the first 5 days. Smooth slow release occurred
between days 5 and 12, with a cumulative release percentage of
65.5% (star FA-PLA-TPGS nanoparticles) and 44.3% (linear FA-PLA-TPGS
nanoparticles). During days 12 to 16, the release reached a plateau,
with a cumulative release percentage of 70.7% at day 14.
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complete Mini protease inhibitors) and equal amounts of
protein were subjected to Western blotting analysis. The
protein levels were normalized to β-actin.
Statistical methods
All experiments were performed at least three times
unless otherwise mentioned. Student’s t test statistical ana-
lysis was carried out with SPSS 13.0 software, with p <0.05
considered to indicate a significant difference.
Results and discussion
Size, surface morphology, zeta potential, and entrapment
efficiency
Particle size and surface properties of the nanoparticles
play a crucial role in drug-release kinetics, cellular uptakeFigure 3 CLSM images of MCF-7/HER2 cells after determined time of
were green, and the cell nuclei were stained by DAPI (blue). The cellular uptake
filter and DAPI filter: (A) After 12 h incubation with coumarin 6-NPs, (B) after 24
coumarin 6-NPs. Scale bar 10 μm.behavior, as well as in vivo pharmacokinetics and tissue
distribution [24]. The particle size and size distribution of
the FA-DM1-NPs were displayed in Table 1. According to
PDI, ZP (mV), particle size (nm), LC (%) and EE (%)
parameters, star-shaped folate-core PLA-TPGS copoly-
mer nanoparticles displayed perfect advantages as an
efficient drug-delivery vehicle. The physical proper-
ties of the FA-DM1-NPs were displayed in Figure 1.
1H NMR (CDCl 3): a (δ =1.61 ppm, LA repeating
unit: -CHCH 3), b (δ =5.19 ppm, LA repeating unit: -CHCH
3), c (δ =3.65 ppm, TPGS repeating unit: -CH 2 CH 2
O-), d (δ =0.52 to 2.30 ppm, FA moiety: -CH- and -CH2-),
and e (δ =4.41 ppm, terminal hydroxyl group of FA-
PLA: -CHOH). The average hydrodynamic size of the FA-
DM1-NPs is approximately 126.6 ± 3.5 nm in diameter,
which is in the excellent size range for readily accumulat-
ing in tumor vasculature due to the enhanced permeation
and retention effects [30,32].
In vitro release profiles
The in vitro drug release profiles of the FA-DM1-NPs in
PBS (pH 7.4) in the first 30 days were shown in Figure 2.
The continuous release of drugs from the polymeric
nanoparticles could occur either by diffusion of the drug
from the polymer matrix or by the erosion of the poly-
mer [33,34]. The initial burst release in the first 5 days
was due to the drug encapsulated in the periphery of the
nanoparticles, while the subsequent sustained release
was predominantly attributed to the diffusion of the
drug which was well entrapped in the core of nanoparti-
cles. The DM1 release from the linear FA-PLA-TPGS
nanoparticles and star FA-PLA-TPGS nanoparticles dis-
played an initial burst of 39.2 and 53.4% in the first
5 days, respectively. The accumulative DM1 release in
the first 30 days was found in the following order: star FA-
PLA-TPGS nanoparticles (65.5%) > linear FA-PLA-TPGS
nanoparticles (44.3%). The star FA-PLA-TPGS nanoparti-
cles displayed the fastest drug release, indicating that theincubation with coumarin 6-NPs. The coumarin 6-loaded nanoparticles
was visualized by overlaying images obtained respectively from the EGFP
h incubation with coumarin 6-NPs, and (C) after 36 h incubation with
Figure 4 MCF-7/HER2 cell viability of FA-DM1-NPs compared with that of S-DM1. At equivalent S-DM1 dose concentration. (A) After 24 h
incubation. (B) After 48 h incubation. (C) After 72 h incubation (*p <0.05, n =3).
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playing faster drug release than that of the linear FA-PLA-
TPGS nanoparticles when the copolymers had the same
molecular weight. Similar results can be found in the
literature [24]. The generally sustained and controlled
release profile of DM1 facilitates the application of
nanoparticles for the delivery of anticancer drugs.
Cellular uptake of fluorescent FA-PLA-TPGS nanoparticles
It has been demonstrated that the therapeutic effects of
drug-loaded nanoparticles depend on internalization and
sustained retention of the nanoparticles by diseased cells
[35,36]. The studies in vitro were capable of providing
some circumstantial evidence to show the advantages ofFigure 5 In vitro growth inhibitory effects of S-DM1 and FA-DM1-
NPs on MCF-7/HER2 cells. The anticancer effects of FA-DM1-NPs and
S-DM1 were tested at concentrations of 0.001, 0.01, 0.1, and 1.0 and
10.0 μg/mL after treatment for 48 and 72 h, respectively. Both drug
inhibited the growth of MCF-7/HER2 cells in a dose-dependent
manner, but the effect on FA-DM1-NPs had no difference with that of
S-DM1 in the concentration range of 0.01 to 10.0 μg/mL (p >0.05).nanoparticle formulation over free drug. Coumarin 6
served as a fluorescent probe in an attempt to represent
the drug in the nanoparticles for visualization and quan-
titative analysis of cellular uptake of the nanoparticles
[37,38]. Figure 3 show the images of tumor cells after
determined time (12, 24, and 36 h) of incubation with
coumarin 6-loaded FA-PLA-TPGS nanoparticle disper-
sion in DMEM at the concentration of 250 μg/mL. It
can be seen from this figure that, with the extension of
the schedule, the green fluorescent in cells continuously
enhanced, indicating that the fluorescent nanoparticles
had been internalized into these MCF-7/HER2 cells.
In vitro MCF-7/HER2 cells viability and sensitivity
Human MCF-7/HER2 cells were applied to investigate
the cytotoxicity of DM1-loaded nanoparticles. The S-
DM1 was designed as the positive control. The different
groups of nanoparticles were sterilized by gamma radi-
ation. Figure 4 displayed the in vitro cell viability of FA-
DM1-NPs at equivalent S-DM1 concentrations of 1.25,
2.5, 5.0, and 10.0 μg/mL. A quantitative colorimetric
assay of MTT was used to determine the percentage of
viable cells [30,39]. From Figure 4, it can be concluded
that the cell suppression of S-DM1 and FA-DM1-NPs
showed both dose- and time-dependent responses. The
cell viability decreased steadily with increasing drug dose
and incubation time, especially for FA-DM1-NPs. Al-
though the growth inhibition efficacy of FA-DM1-NPs
was stronger than that of S-DM1 in the concentration
range of 0.1 to 10 μg/mL, there were no significant dif-
ferences between FA-DM1-NPs and S-DM1 statistically
(Figure 4). Next, we compared the effects of S-DM1 and
FA-DM1-NPs on MCF-7/HER2 cell lines in vitro. After
48- and 72-h incubation, respectively, FA-DM1-NPs
and S-DM1 inhibited the growth of MCF-7/HER2
cells in a dose-dependent manner. The growth inhib-
ition of FA-DM1-NPs was stronger compared with
Figure 6 Effect of FA-DM1-NPs and S-DM1 on expression levels of apoptosis-related proteins in MCF-7/HER2 cells. Following the
treatment of breast cancer cells with therapeutic concentrations of drugs (5.2 µg/mL S-DM1 and 10 µg/mL FA-DM1-NPs equivalent DM1 5.0 µg/mL,
respectively), the expression levels of procaspase-3/-8/-9 and Bcl-2 were analyzed by Western blot (A) and Gel-Pro Analyzer 4.0 software (B).
**p <0.01, *p <0.05 vs. control. Results were representative of three independent experiments. Δp <0.05 vs. S-DM1 treatment group.
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10.0 μg/mL (p >0.05, n =3) (Figure 5). But statistically,
there were no significant differences between FA-DM1-
NPs and S-DM1.
Effect of drug on the expression levels of apoptosis-
related proteins
In order to study the effect of FA-DM1-NPs and DM1 on
the expression levels of apoptosis-related proteins, treat-
ment concentrations of drugs were administered to MCF-7
cells for 48 h. And Western blot analysis was conducted toFigure 7 Growth inhibitory effects of FA-DM1-NPs and S-DM1
on MCF-7/HER2 cells in vivo. SCID mice with tumor cell xenografts
were treated with PBS, FA-NPs (6 μg/g, i.v., n =10), FA-DM1-NPs
(10 μg/g equivalent DM1 5 μg/g, i.v., n =10), or S-DM1 (5.2 μg/g
equivalent DM1 5 μg/g, i.v., n =10). Drug administration was
conducted on days 10, 13, and 16, respectively. FA-NPs had no effect
on tumor growth. Tumor shrinkage was seen by DM1 from day 38.
From day 34 onwards, all of the FA-DM1-NP-treated tumors
were unmeasurable.investigate the expression levels of Bcl-2 and procaspase-
3/-8/-9 proteins (Figure 6). It was found that following
treatment with FA-DM1-NPs or DM1, the procaspase-3
and procaspase-9 protein expression levels significantly de-
clined, while no significant differences were observed in the
expression levels of procaspase-8 protein. Our data demon-
strated that DM1 and FA-DM1-NPs-induced apoptosis
may occur through the mitochondria-mediated caspase-3
and caspase-9 pathways.
Effect of DM1 NPs on xenografts
MCF-7/HER2 cells were capable of forming xenograft sub-
cutaneous tumors in SCID mice in 7 days (n =40, mean
tumor volume 30 ± 3 mm3). Thereafter, treatments with S-
DM1 (n =10) or FA-DM1-NPs (n =10) were administered
on days 10, 13, and 16. FA-NPs (n =10) was used as nega-
tive control agent, and PBS as control agent (n =10). A
rapid tumor shrinkage was observed by S-DM1 from day
46 (Figure 7). Histologically, a pathological complete re-
sponse was seen in five mice (5/10), and residual tumor
cells in the other five (5/10) at the end of the experiment
(day 50) (Figure 8). Overall, the effect of FA-DM1-NPs on
MCF-7/HER2 tumor growth was much stronger than that
of S-DM1. From day 34 onwards, almost all of the FA-
DM1-NP-treated tumors were unmeasurable. Histologi-
cally, a pathological complete response was seen in eight
mice (8/10) and residual tumor cells in the other two
(2/10) at the end of the experiment (day 50) (p <0.05)
(Figure 7). FA-NPs and PBS had no effect on tumor
growth. It can be seen from Figure 7 that FA-DM1-NPs
can effectively control MCF-7/HER2 xenograft tumor.
Pathological analysis
Synergistic antitumor activities could be obtained by the
use of combinations of S-DM1 and star FA-PLA-TPGS-
NPs. As shown in Figure 8, residual tumor cells were
Figure 8 Residual cancer cells in FA-DM1-NPs treated MCF-7/HER2 xenografts. Residual cancer cell aggregates were found from the tumor
samples in two of ten xenografted mice after FA-DM1-NP treatment. The level of oncogene Her2 (FISH), tumor cell division phase index Ki-67
(IHC) positive ratio, and the expression level of HER2 (IHC) in the MCF-7/HER2 cells of the FA-DM1-NP post-treatment were lower compared with
those of pre-treatment (×100). Yellow scale bar 10 μm and black scale bar 50 μm. The few surviving in the tumor tissue FA-DM1-NP treatment
group after treatment, the level of oncogene Her2, tumor cell division phase index Ki-67, and the HER2 expression level of tumor cells were
significantly reduced, even disappeared, which suggested that the existence of the typical MCF-7/HER2 tumor cells had significantly declined.
This may be due to FA-DM1-NPs combining folate receptor (FR) of the tumor cells effectively to induce the FA-DM1-NPs internalize and release
the entrapped drug DM1, and then play the biological effects of antitumor. These data suggested that FA-DM1-NPs can be more effectively
enriched in FR+ MCF-7/HER2 tumor cells and have more effective antitumor as compare to S-DM1.
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the FA-DM1-NP treatment group. Tumor cell nuclear
structure showed that cell division phase decreased sig-
nificantly compared to pre- FA-DM1-NP treatment. The
fraction of proliferating cells (confirmed by Ki-67 immu-
nohistochemical staining) among tumor cells was small
compared to pre-treatment (Figure 8). Confirmed by
FISH, oncogene Her2 was amplified in MCF-7/HER2 cells
of the pre- and postdrug treatment. But the Her2 level at
pre-treatment was much higher than that at post-treatment
(Figure 8). Tumor cell division phase index Ki-67 (IHC)
positive ratio and the expression level of HER2 (IHC) in
MCF-7/HER2 cells of the FA-DM1-NP post-treatment
were lower compared with those of pre-treatment. HER2 is
an excellent target for an antibody-drug conjugate as it is
highly overexpressed on HER2-positive cancer cells. After
binding to HER2, DM1 is internalized by endocytosis and
degraded in lysosomes, causing the release of the active
metabolite DM1 which inhibits Her2- and HER2-positive
cancer cell division and induces cell death by blocking the
spindle apparatus. So, after FA-DM1-NP pre-treatment,
tumor cell division phase index-, Her2 oncogene-, and
HER2-positive cancer cells significantly reduced com-
pared with FA-DM1-NP post-treatment. In conclusion,
the FA-DM1-NPs offered considerable potential as an
ideal candidate for in vivo drug delivery.
Conclusions
There is no doubt that DM1 has provided significant clin-
ical benefit in patients with breast cancer [36,37]. Neverthe-
less, primary (de novo) and secondary (acquired) resistanceand side effects represent real clinical challenges [25,40].
FA-DM1-NPs showed high stability and desired surface
properties in favor of cellular uptake. Meanwhile, FA-DM1-
NPs can be targeted to FR+ cancer cells and improve DM1
concentration in the target tissues, reduce nonspecific dis-
tribution and side effects of DM1, inhibit tumor cell prolif-
eration, and promote apoptosis of tumor cells in the effects
of biological synergy, which has a potential to establish new
treatment paradigms.
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